References

Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncology. 2013;31:88–94.

Ahn IE, Underbayev C, Albitar A et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469.

Barr P, Robak T, Owen CJ, Tedeschi A t al. Updated efficacy and safety from the phase 3 RESONATE-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128:234.

Barr PM, Brown JR, Hillmen P et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017; 129:2612–5.

Burger JA, Tedeschi A, Barr PM et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New Engl J Med. 2015;373: 2425–37.

Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med. 2013;369:32–42.

Byrd JC, Brown JR, O’Brien, S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New Engl J Med. 2014;371: 213–23.

Byrd JC, Furman RR, Coutre SE et al. Three-year follow-up of treatment naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–506.

Chanan-Khan A, Cramer P, Demirkan F et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology. 2017;17:200–11.

Coutre S, Byrd JC, Hillmen P et al. Integrated and long-term safety analysis of ibrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016;128:4383.

de Zwart L, Snoeys J, De Jong J et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharm Therapeut. 2016;100:548–57.

Dreyling M, Jurczak W, Jerkeman M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2017;387:770–8.

Eichhorst B, Robak T, Montserrat E et al. Appendix 6: chronic lymphocytic leukaemia: eUpdate published online September 2016 (http:// www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016; 27:v143–v144.

Fraser G, Cramer P, Demirkan F et al. Ibrutinib Plus Bendamustine and Rituximab in Previously Treated CLL/SLL: 2-Year Follow-up Including MRD From the HELIOS Study. 2016. Available at: https://www.myoncologia.pt/images/noticias/2016_EHA_Fraser_et_al_HELIOS_2Y_FUP_oral_presentation.pdf.

Gillespie CD, Hurvitz KA. Prevalence of hypertension and controlled hypertension – United States. MMWR Suppl. 2013;62:144–8.

Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–60.

Herman SEM, Niemann CU, Farooqui M et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–96.

Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107:13075–80.

Jones JA, Hillmen P, Coutre SE al. Use of anticoagulants and antiplatelets in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017;178:286–91.

Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothor Surg. 2016;50:e1–e88.

Levade M, David E, Garcia C et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991–5.

Maddocks KJ, Ruppert AS, Lozanski G et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80.

Makris M, Van Veen JJ, Tait CR et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160:35–46.

Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Practice Guidelines for the management of arterial hypertension. Blood Pressure. 2014;23:3–16.

Moreno C, Byrd JC, Hillmen P et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the resonate study with up to four years of follow-up. Haematologica. 2017;102:1–882.

Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymph Myeloma. 2009;9:365–70.

O’Brien S, Jones JA, Coutre S et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the Phase II RESONATE TM-17 trial. Blood. 2014;124: 327.

Rogers KA, Ruppert AS, Bingman A et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia autoimmune cytopenias during ibrutinib treatment. Leukemia. 2016;30:346–50.

Shanafelt TD, Parikh SA, Noseworthy PA et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymph. 2017;58:1630–9.

Shatzel JJ, Olson SR, Tao DL et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haem. 2017;15:835–47.

Sun C, Tian X, Lee YS et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–9.

Thompson PA, Levy V, Tam CS et al. The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): an international study. Blood. 2016;128:3242.

Vitale C, Ahn IE, Sivina M et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016;101:e254–e258.

Wang ML, Lee H, Chuang H et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2017;17:48–56.

Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic leukemia, version 1.2017. J Natl Comp Cancer Network. 2017; 15:293–311.

Woyach JA. How I manage ibrutinib refractory chronic lymphocytic leukemia. Blood. 2017;129:1270.

Woyach JA, Smucker K, Smith LL et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.

Key Publications

 

Login/ Register Maximise Minimise